Galanin: A Literature Course in Six Modules

Galanin appears in the literature as a neuropeptide and as a pharmacological target, not as a marketed drug. This course summarises what peer-reviewed papers have reported about it, module by module, using only the sources listed in the References section. This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decision. Nothing here describes a protocol, and no module should be read as a suggestion that galanin be administered to anyone.

Each module closes with an explicit statement of what the cited evidence cannot support. Readers who want depth are pointed to the original abstracts rather than to secondary summaries.

Module 1: What Galanin Is and How It Has Been Studied

Definition and class

Galanin is a neuropeptide — an endogenous signalling peptide produced by neurons and by some peripheral and endocrine tissues — that acts on a family of cell-surface receptors. A 2021 review in Journal of Cell Communication and Signaling assembled the galanin–galanin receptor signalling network and described galanin as a widely distributed neuropeptide whose actions are transduced by G-protein-coupled receptors across neural and non-neural tissues (PMID 33136286). Earlier pharmacology reviews placed galanin within the broader neuropeptide class and catalogued the receptor subtypes and ligands available to study it (PMID 23233848).

Forms and structure

Galanin has been studied both as the full-length endogenous peptide and as fragments and analogues generated for receptor pharmacology. A 2022 biophysical study reported that the neuropeptide galanin adopts an irregular secondary structure rather than a single stable fold (PMID 35994823), a finding relevant to how the peptide is thought to engage its receptors. Reviews of galanin receptor ligands have described how peptide fragments, chimeric peptides and modified analogues were built to probe subtype selectivity (PMID 15944002).

How it has been studied

The methods used in the verified literature fall into a few buckets:

• Receptor pharmacology. Subtype classification, cloning and ligand characterisation were the focus of reviews summarising GalR1, GalR2 and GalR3 (PMID 10689365).
• Structural biology. Conformational analysis of the peptide itself was reported in 2022 (PMID 35994823).
• Animal electrophysiology and behaviour. Recordings from identified neurons and behavioural paradigms in rodents and fish were used to test circuit-level roles (PMID 41651655, PMID 32783809).
• Human observational measurement. Serum concentrations and tissue expression were compared between groups in clinical samples (PMID 33534034, PMID 35707368).

Limits of the evidence in Module 1

None of the cited work in this module tested galanin as an administered agent in humans. Definitional and structural papers describe what the molecule is and how it behaves in vitro; they do not establish any clinical role, and they do not report doses, schedules or outcomes in people.

Module 2: Mechanism as Described in the Literature

Three receptor subtypes

The mechanistic literature is organised around three receptors. A 2000 review in Trends in Pharmacological Sciences described galanin receptor subtypes GalR1, GalR2 and GalR3 as distinct G-protein-coupled receptors with different distributions and coupling profiles (PMID 10689365). A 2012 review in Frontiers in Endocrinology similarly summarised the subtypes together with the peptide and non-peptide ligands developed to distinguish them (PMID 23233848).

In broad terms, the reviews reported that GalR1 and GalR3 couple predominantly to inhibitory Gi/o proteins, while GalR2 has been described as coupling to Gq/11-linked pathways in addition to Gi/o, giving the system the capacity for both inhibitory and excitatory downstream effects depending on which subtype is engaged (PMID 10689365, PMID 23233848). The 2021 network review extended this picture by mapping the intracellular signalling partners and tissue contexts reported for galanin receptor activation (PMID 33136286).

Circuit-level mechanism

Two recent papers illustrate how subtype-specific mechanism has been tested directly. A 2026 eNeuro study reported that galanin inhibited histaminergic neurons and attributed that inhibition to galanin receptor 1 (PMID 41651655). A 2025 eLife paper described a multifaceted role for galanin in brain excitability, with researchers reporting that the peptide's net effect on excitability depended on the cellular and network context rather than acting in a single direction (PMID 40613532).

Peripheral sensory mechanism

Mechanistic work has not been limited to the brain. A 2020 report in Physiological Reports found that galanin suppressed visceral afferent responses to noxious mechanical and inflammatory stimuli, positioning the peptide as a modulator of sensory signalling from the viscera (PMID 31960596).

Limits of the evidence in Module 2

Mechanism is not outcome. The reviews and electrophysiology papers explain how receptor activation changes cell behaviour in defined preparations; they do not demonstrate that engaging these receptors produces any particular clinical result. Because GalR1, GalR2 and GalR3 have been described as having different coupling and distribution (PMID 10689365), findings obtained with one ligand or in one tissue cannot be generalised across the system.

Module 3: Reported Outcomes by Study

The table below lists what each verified primary study examined and what researchers reported. No entry should be read as a benefit claim; several are descriptive measurements rather than intervention studies.

Reading the outcome literature carefully

Three distinctions matter when interpreting this set. First, direction of effect is model-specific: galanin was reported to suppress sensory afferent responses in one preparation (PMID 31960596) and to inhibit a specific neuronal population through GalR1 in another (PMID 41651655), while a separate paper emphasised that its influence on brain excitability was not unidirectional (PMID 40613532).

Second, animal behaviour studies test circuit necessity, not therapeutic effect. The medaka work linked a male-predominant galanin population to androgen-dependent aggressive chases (PMID 32783809); that is a statement about a fish behavioural circuit, not about human behaviour.

Third, human data in this set are correlational. Measuring serum galanin in children with autism spectrum disorder (PMID 33534034) or profiling galanin expression in colorectal tumour tissue (PMID 35707368) describes associations between an endogenous peptide and a condition. Neither design can establish causation, and neither involved administering galanin.

Limits of the evidence in Module 3

There are no randomised controlled trials of galanin administration in the verified set, no dose-ranging data, and no efficacy endpoints of the kind regulators require. The studies above used different species, preparations and endpoints, so they cannot be pooled, and a result in one model does not predict a result in another.

Module 4: Galanin Side Effects: What Studies Report

The honest summary is that the verified literature contains no systematic adverse-event reporting for galanin, because none of these papers was a human safety or tolerability trial. What the literature does contain are physiological effects observed in experimental models, which is a different category of information.

Effects reported in the cited work that are relevant to a safety discussion include suppression of visceral afferent responses to noxious mechanical and inflammatory stimuli (PMID 31960596), inhibition of histaminergic neurons through galanin receptor 1 (PMID 41651655), and context-dependent changes in brain excitability (PMID 40613532). Behavioural findings include a reported relationship between galanin and perseveration in a rodent paradigm (PMID 15829223) and mediation of androgen-dependent aggressive chases by a male-predominant galanin population in medaka (PMID 32783809). Whether any of these translate into clinically meaningful effects or risks in humans was not tested in these papers.

Receptor pharmacology reviews add a further consideration: because subtypes differ in coupling and distribution, a non-selective agent acting at GalR1, GalR2 and GalR3 would be expected to engage multiple pathways simultaneously (PMID 10689365, PMID 23233848). That is a theoretical point drawn from the reviews, not an observed adverse event.

Limits of the evidence in Module 4

Absence of published adverse events is not evidence of safety. No cited study collected treatment-emergent adverse events, vital signs, laboratory safety panels or long-term follow-up in humans, so no tolerability profile can be constructed from this literature.

Module 5: Pharmacokinetics Where Data Exist

The verified literature does not include human or animal pharmacokinetic studies of galanin — no absorption, distribution, metabolism or elimination parameters, no half-life, and no bioavailability figures. What it does offer is indirect context.

The 2022 structural study reported that galanin adopts an irregular secondary structure (PMID 35994823), which is the kind of property that structure–activity work considers when evaluating peptide stability and receptor engagement. Ligand reviews described sustained effort to develop galanin receptor ligands, including modified peptides and analogues intended to improve subtype selectivity (PMID 15944002, PMID 23233848). The existence of that effort implies, but does not document, the usual constraints on native peptides.

Limits of the evidence in Module 5

Readers should treat the pharmacokinetics of galanin as undocumented in this source set. Any specific half-life, clearance route or route-of-administration comparison circulating elsewhere is not supported by the papers cited here, and this page does not supply one.

Module 6: Regulatory Status, Stated Factually

Galanin is not an approved drug product in the United States. There is no FDA-approved galanin medicine, no approved galanin receptor agonist marketed as such, and therefore no approved labelling, indication or dosing information for galanin as a therapeutic.

Galanin peptide and its analogues are handled as research-use-only (RUO) materials in the scientific supply chain. RUO labelling means a material is intended for laboratory investigation and is not intended for diagnostic or therapeutic use in humans or animals; it carries no FDA finding of safety or efficacy and no requirement for the manufacturing controls applied to drug products.

On compounding: US pharmacy compounding under sections 503A (traditional pharmacies) and 503B (outsourcing facilities) of the Federal Food, Drug, and Cosmetic Act generally requires that a bulk drug substance be the subject of an applicable USP or NF monograph, be a component of an FDA-approved drug, or appear on the relevant FDA bulk drug substances list. Galanin is not an approved drug component, and this page makes no claim that it satisfies any compounding pathway.

Galanin is also not a dietary ingredient marketed under the dietary supplement framework, and peptides of this type generally fall outside that category. This section describes publicly stated regulatory categories and is not legal advice; rules differ by country and by state, and questions about a specific situation belong with a qualified professional.

Limits of the evidence in Module 6

Regulatory status describes how a substance is classified, not what it does. Nothing in this module implies that galanin has been evaluated for human use, and regulatory categories change over time.

What the Studies Did Not Test

Pulling the six modules together, the verified literature on galanin did not test:

1. Human administration. No cited study gave galanin to human participants, so no dose, route or schedule can be described from this evidence base.
2. Clinical efficacy. The human papers measured endogenous galanin — serum concentrations in children with autism spectrum disorder (PMID 33534034) and tissue expression in colorectal cancer (PMID 35707368) — rather than testing an intervention.
3. Safety and tolerability. No adverse-event collection, laboratory monitoring or long-term follow-up appeared in any cited paper.
4. Pharmacokinetics. No absorption, half-life or clearance data were reported; structural work described the peptide's irregular secondary structure only (PMID 35994823).
5. Subtype-selective therapeutics. Reviews catalogued ligands developed for GalR1, GalR2 and GalR3 (PMID 15944002, PMID 23233848) without reporting approved clinical agents.
6. Cross-species translation. Findings in fish (PMID 32783809) and rodent preparations (PMID 15829223) were not extended to humans in these papers.

Galanin is best understood, from this literature, as an endogenous signalling peptide and an active research target whose receptor biology has been mapped in considerable detail (PMID 33136286) while its translational profile remains largely unstudied. This page is for educational purposes only and is not medical advice; consult a licensed physician with any question about a medical condition or treatment.

References

• An assembly of galanin-galanin receptor signaling network (Journal of Cell Communication and Signaling, 2021)
• Galanin receptors and ligands (Frontiers in Endocrinology, 2012)
• The neuropeptide galanin adopts an irregular secondary structure (Biochemical and Biophysical Research Communications, 2022)
• Galanin suppresses visceral afferent responses to noxious mechanical and inflammatory stimuli (Physiological Reports, 2020)
• Galanin receptor subtypes (Trends in Pharmacological Sciences, 2000)
• Galanin receptor ligands (Neuropeptides, 2005)
• Galanin Inhibits Histaminergic Neurons via Galanin Receptor 1 (eNeuro, 2026)
• Multifaceted role of galanin in brain excitability (eLife, 2025)
• Galanin and perseveration (Brain Research, 2005)
• Male-predominant galanin mediates androgen-dependent aggressive chases in medaka (eLife, 2020)
• Serum Galanin in Children with Autism Spectrum Disorder (Child Psychiatry and Human Development, 2022)
• Evaluation of Galanin Expression in Colorectal Cancer: An Immunohistochemical and Transcriptomic Study (Frontiers in Oncology, 2022)